Picture2.JPG
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
September 19, 2024 07:00 ET | Vivos Therapeutics, Inc
LITTLETON, Colo., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the...
Picture2.JPG
Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
August 14, 2024 16:05 ET | Vivos Therapeutics, Inc
Revenue Increased 19% both Sequentially and Year over Year Operating Expenses Decreased 31%, Marking Eight Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting...
Picture2.JPG
Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call
August 14, 2024 07:30 ET | Vivos Therapeutics, Inc
LITTLETON, Colo., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the...
Picture2.JPG
Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update
May 14, 2024 16:05 ET | Vivos Therapeutics, Inc
Vivos Expanding its Revenue Generating InitiativesAs Operating Expenses Decrease 22%, Representing Seven Consecutive Quarters ofYear Over Year Improvement Due to Successful Cost Cutting Initiatives ...
Picture2.JPG
Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call
May 14, 2024 07:30 ET | Vivos Therapeutics, Inc
LITTLETON, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development...
Picture2.JPG
Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update
March 28, 2024 16:05 ET | Vivos Therapeutics, Inc
Positive Business Momentum and Sales Pipeline Growth Following FDA 510(k) Clearance of Vivos’ Proprietary Oral Medical Devices to Treat Severe Obstructive Sleep Apnea Annual Operating Expenses...